SCHEMBL11889243

SCHEMBL11889243

CNc1ncc2cc(-c3c(C)ccc4c(Nc5cncnc5)nn(C)c34)ccc2n1

nearest known ligand 0.54

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
LCK P06239 16/20 0.54
BRAF P15056 7/20 0.54
KDR P35968 13/20 0.53
MAPK14 Q16539 13/20 0.53
TEK Q02763 2/20 0.53
EIF2AK3 Q9NZJ5 1/20 0.38
EIF2AK4 Q9P2K8 1/20 0.38
JAK3 P52333 9/20 0.37
FGFR4 P22455 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11889033 0.91 LCK (0.53) LCKBRAFKDRMAPK14TEK
SCHEMBL5470763 0.90 LCK (0.54) LCKBRAFKDRMAPK14TEK
SCHEMBL11888900 0.90 LCK (0.58) LCKBRAFKDRMAPK14TEK
SCHEMBL11889057 0.90 LCK (0.58) LCKBRAFKDRMAPK14TEK
SCHEMBL11889249 0.90 LCK (0.60) LCKBRAFKDRMAPK14TEK
SCHEMBL11888939 0.89 LCK (0.58) LCKBRAFKDRMAPK14TEK
SCHEMBL11889133 0.89 LCK (0.51) LCKBRAFKDRMAPK14TEK
SCHEMBL11888970 0.88 LCK (0.54) LCKBRAFKDRMAPK14TEK
SCHEMBL11889208 0.88 LCK (0.57) LCKBRAFKDRMAPK14TEK
SCHEMBL11889318 0.88 LCK (0.71) LCKBRAFKDRMAPK14TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976836-B9 NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES AMGEN INC (US) 2013-02-06 EP disclosed
EP-1976836-B1 NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES AMGEN INC (US) 2012-08-22 EP disclosed
EP-2481729-A1 Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases Amgen Inc. (US) 2012-08-01 EP disclosed